GO:0004595 pantetheine-phosphate adenylyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004595 (pantetheine-phosphate adenylyltransferase activity, also called PPAT) catalyzes the reversible transfer of an adenylyl group from ATP to pantetheine 4'-phosphate, yielding 3'-dephospho-CoA and diphosphate.
• PPAT is the penultimate enzyme of the coenzyme A (CoA) biosynthetic pathway and is often physically associated with dephospho-CoA kinase, forming a bifunctional enzyme complex.
• The enzyme is essential for CoA-dependent metabolism, including fatty acid synthesis, tricarboxylic acid cycle function, and acyl-carrier-protein-dependent pathways.
• PPAT is a validated antibacterial drug target, with fragment-based and structure-guided inhibitors showing Gram-negative activity.
• CRISPR interference (CRISPRi) has been used to chemically validate Mycobacterium tuberculosis PPAT as a drug target.
• Crystal structures of PPAT from Enterococcus faecalis and other bacteria reveal the active-site architecture and substrate-binding residues.
Description
Pantetheine-phosphate adenylyltransferase (PPAT) is the enzyme encoded by GO:0004595, a molecular function that catalyzes the reaction ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate. This reaction is the penultimate step in the biosynthesis of coenzyme A (CoA), a universal acyl-group carrier and redox cofactor. PPAT is therefore central to cellular metabolism, and its activity is required for the production of CoA from pantothenate in bacteria and eukaryotes. The enzyme is also known as dephospho-CoA pyrophosphorylase, 3'-dephospho-CoA pyrophosphorylase, and phosphopantetheine adenylyltransferase. Because CoA is essential for fatty acid synthesis, the tricarboxylic acid cycle, and numerous acylation reactions, PPAT has attracted attention as a target for antibacterial drug discovery. In many bacteria, PPAT forms a bifunctional complex with dephospho-CoA kinase, the enzyme that catalyzes the final step of CoA biosynthesis, ensuring efficient substrate channeling. Structural and biochemical studies have defined the active site and substrate-binding determinants of PPAT from several bacterial species, including Enterococcus faecalis and Gram-negative pathogens. This article summarizes the mechanism, key genes, disease relevance, and research methods for studying GO:0004595, with a focus on how CRISPR-based models can be used to interrogate its function.
pantetheine-phosphate adenylyltransferase activity At A Glance
| GO ID | GO:0004595 |
|---|---|
| GO term | pantetheine-phosphate adenylyltransferase activity |
| Ontology | molecular_function |
| Synonym | 3'-dephospho-CoA pyrophosphorylase activity; ATP:pantetheine-4'-phosphate adenylyltransferase activity; dephospho-CoA pyrophosphorylase activity; phosphopantetheine adenylyltransferase activity; PPAT activity |
| Major function | Catalyzes the penultimate step of coenzyme A biosynthesis: ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate |
| Reaction direction | Reversible in vitro; biosynthetic in vivo |
| Cofactors | Divalent metal ions (e.g., Mg2+ or Mn2+) |
| Pathway | Coenzyme A biosynthesis |
| Subcellular location | Cytosol (bacteria and eukaryotes) |
What Is GO:0004595?
GO:0004595, pantetheine-phosphate adenylyltransferase activity, is defined as the catalysis of the reaction ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate. In this reaction, the enzyme transfers an adenylyl group from ATP to the 4'-phosphate of pantetheine 4'-phosphate, releasing diphosphate and forming 3'-dephospho-CoA. This activity is also known as dephospho-CoA pyrophosphorylase, dephospho-CoA diphosphorylase, and phosphopantetheine adenylyltransferase (PPAT). The reaction is reversible in vitro, but in cells it functions in the direction of 3'-dephospho-CoA synthesis. PPAT belongs to the nucleotidyltransferase superfamily and requires divalent metal ions for activity.
Why Is pantetheine-phosphate adenylyltransferase activity Important in Cell Biology?
PPAT activity is essential for coenzyme A biosynthesis, and CoA is required for a vast array of metabolic processes, including fatty acid synthesis and oxidation, the tricarboxylic acid cycle, and protein acylation. Because many pathogenic bacteria rely on their own CoA biosynthetic pathway, PPAT is a promising target for antibiotics, and inhibitors have shown activity against Gram-negative bacteria. In Mycobacterium tuberculosis, chemical validation of PPAT using fragment linking and CRISPR interference has demonstrated that the enzyme is essential for growth. Structural studies of PPAT from Enterococcus faecalis and other bacteria have provided a template for rational inhibitor design. Thus, understanding GO:0004595 is important for both basic metabolism research and antimicrobial drug discovery.
• PPAT catalyzes the penultimate step of coenzyme A biosynthesis, a pathway essential for acyl-group transfer and redox metabolism.
• CoA is required for fatty acid synthesis and degradation, the TCA cycle, and numerous acylation reactions.
• PPAT is a validated antibacterial target, with inhibitors active against Gram-negative pathogens.
• In Mycobacterium tuberculosis, CRISPRi-mediated knockdown confirms PPAT is essential for growth.
• The enzyme forms a bifunctional complex with dephospho-CoA kinase in some bacteria, enabling substrate channeling.
• Crystal structures of PPAT from Enterococcus faecalis reveal the active-site architecture and substrate-binding residues.
• PPAT is conserved across bacteria and eukaryotes, making it a model enzyme for studying nucleotidyltransferase mechanisms.
• Inhibition of PPAT disrupts CoA homeostasis and has downstream effects on lipid metabolism and cell envelope biosynthesis.
• Fragment-based drug discovery has yielded potent PPAT inhibitors with drug-like properties.
• PPAT activity can be measured enzymatically, enabling high-throughput screening for inhibitors.
Molecular Mechanism of pantetheine-phosphate adenylyltransferase activity
Substrate binding and active-site architecture
In simple terms: The enzyme grabs ATP and pantetheine 4'-phosphate in its active site.
PPAT binds ATP and pantetheine 4'-phosphate in a conserved active site. Crystal structures of Enterococcus faecalis PPAT in the ligand-unbound state and in complex with ATP and pantetheine reveal the residues that coordinate the substrates. The enzyme belongs to the nucleotidyltransferase superfamily and requires divalent metal ions for catalysis. The active site is formed by a Rossmann-like fold that positions the ATP phosphates for attack by the pantetheine 4'-phosphate hydroxyl.
Catalytic mechanism and adenylyl transfer
In simple terms: The enzyme moves an adenylyl group from ATP onto pantetheine 4'-phosphate.
The reaction catalyzed by PPAT is: ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate. The enzyme transfers the adenylyl group from ATP to the 4'-phosphate of pantetheine 4'-phosphate, releasing diphosphate. This is a nucleotidyltransferase reaction that proceeds via a pentavalent transition state, with divalent metal ions stabilizing the leaving group. The reaction is reversible in vitro, but in cells it operates in the direction of 3'-dephospho-CoA synthesis.
Bifunctional complex with dephospho-CoA kinase
In simple terms: In some bacteria, PPAT works together with the next enzyme in the pathway.
In Brevibacterium ammoniagenes, separate enzymes catalyze the final two steps of coenzyme A biosynthesis, and PPAT has been purified as a distinct protein. In other organisms, PPAT forms a bifunctional enzyme complex with dephospho-CoA kinase, the enzyme that catalyzes the final step of CoA biosynthesis. This complex allows substrate channeling, in which 3'-dephospho-CoA produced by PPAT is directly transferred to dephospho-CoA kinase, improving pathway efficiency.
Regulation and inhibition
In simple terms: The enzyme can be turned off by inhibitors that block its active site.
PPAT activity can be inhibited by small molecules that compete with ATP or pantetheine 4'-phosphate. Fragment-based drug discovery has yielded inhibitors of PPAT from Gram-negative bacteria, and optimization has produced compounds with antibacterial activity. In Mycobacterium tuberculosis, chemical validation of PPAT using fragment linking and CRISPR interference has confirmed that the enzyme is essential for growth. These studies demonstrate that PPAT is a druggable target and that its activity can be modulated by small molecules.
Key Genes Involved in GO:0004595 pantetheine-phosphate adenylyltransferase activity
The following genes and proteins are directly involved in pantetheine-phosphate adenylyltransferase activity or in the coenzyme A biosynthetic pathway that this enzyme participates in.
| Gene | Major Role | Research Relevance |
|---|---|---|
| coaD (PPAT) | Catalyzes the penultimate step of CoA biosynthesis: ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate | Essential for CoA production; target for antibacterial drug discovery |
| coaE (dephospho-CoA kinase) | Catalyzes the final step of CoA biosynthesis: 3'-dephospho-CoA + ATP = CoA + ADP | Forms a bifunctional complex with PPAT in some bacteria |
| coaA (pantothenate kinase) | Catalyzes the first step of CoA biosynthesis: pantothenate + ATP = 4'-phosphopantothenate + ADP | Regulates flux into the CoA pathway |
| coaB (phosphopantothenoylcysteine synthetase) | Catalyzes the second step of CoA biosynthesis | Part of the CoA biosynthetic pathway |
| coaC (phosphopantothenoylcysteine decarboxylase) | Catalyzes the third step of CoA biosynthesis | Part of the CoA biosynthetic pathway |
| coaX (type III pantothenate kinase) | Alternative pantothenate kinase in some bacteria | Bypasses coaA in certain species |
| ppat (Mycobacterium tuberculosis) | PPAT enzyme in M. tuberculosis | Validated as essential by CRISPRi |
| PPAT (Enterococcus faecalis) | PPAT enzyme in E. faecalis | Crystal structures with ATP and pantetheine |
| PPAT (Gram-negative bacteria) | PPAT enzyme in pathogens such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa | Target of fragment-based inhibitor discovery |
| PPAT (Brevibacterium ammoniagenes) | PPAT enzyme in B. ammoniagenes | Purified as a separate enzyme from dephospho-CoA kinase |
| PPAT (human) | PPAT enzyme in humans (also known as CoaD or PPAT) | Involved in CoA biosynthesis; potential target for metabolic studies |
| CoA synthase (COASY) | Bifunctional enzyme with PPAT and dephospho-CoA kinase domains in eukaryotes | Catalyzes the final two steps of CoA biosynthesis in humans |
| Acyl carrier protein (ACP) | Requires 4'-phosphopantetheine for activity | Downstream consumer of CoA derivatives |
| Fatty acid synthase (FAS) | Requires CoA for acyl transfer | Metabolic pathway dependent on CoA |
| Pyruvate dehydrogenase complex | Requires CoA as a cofactor | TCA cycle and energy metabolism |
| Alpha-ketoglutarate dehydrogenase | Requires CoA as a cofactor | TCA cycle |
| PPAT (Pseudomonas aeruginosa) | PPAT enzyme in P. aeruginosa | Target of antibacterial inhibitors |
| PPAT (Klebsiella pneumoniae) | PPAT enzyme in K. pneumoniae | Target of antibacterial inhibitors |
How Is pantetheine-phosphate adenylyltransferase activity Regulated?
PPAT activity is regulated at multiple levels. In bacteria, the coa operon is controlled by transcriptional regulators that respond to CoA levels. In eukaryotes, the bifunctional enzyme COASY contains both PPAT and dephospho-CoA kinase domains, and its activity is coordinated with the upstream pantothenate kinase step. Small-molecule inhibitors can directly block PPAT activity, and fragment-based approaches have identified compounds that bind the active site. In Mycobacterium tuberculosis, CRISPR interference has been used to titrate PPAT expression, demonstrating that reduced enzyme levels impair growth. These regulatory mechanisms ensure that CoA biosynthesis matches cellular demand for acyl-group carriers and redox cofactors.
pantetheine-phosphate adenylyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| coaD (PPAT) | Bacterial infections; essential for CoA biosynthesis | CRISPR knockout or CRISPRi knockdown in Escherichia coli or Mycobacterium tuberculosis |
| COASY | CoA biosynthesis defects; neurodegenerative disorders | Knockout or point-mutation knock-in in human cell lines |
| coaE | CoA biosynthesis defects | Knockout in bacteria or human cells |
| coaA | CoA biosynthesis defects | Knockout or overexpression in bacterial models |
| PPAT (Gram-negative bacteria) | Antibiotic resistance | CRISPRi knockdown combined with inhibitor treatment |
Bacterial infections and antibiotic resistance
PPAT is essential for CoA biosynthesis in many pathogenic bacteria, and inhibitors of PPAT have shown activity against Gram-negative pathogens. Because antibiotic resistance is a growing problem, PPAT represents a promising target for new antibacterial agents. Fragment-based drug discovery has produced potent PPAT inhibitors with drug-like properties, and chemical validation in Mycobacterium tuberculosis using CRISPR interference has confirmed the enzyme as a drug target. These findings support the development of PPAT inhibitors as novel antibiotics.
Metabolic disorders and CoA homeostasis
CoA is central to fatty acid metabolism, the TCA cycle, and protein acylation, and disruptions in CoA biosynthesis can affect these processes. In humans, the bifunctional enzyme COASY catalyzes the final two steps of CoA biosynthesis, including the PPAT reaction. Mutations in COASY have been associated with neurodegenerative disorders, although the specific role of the PPAT domain in these conditions requires further study. Research on PPAT activity can help clarify how CoA levels are maintained in health and disease.
Cancer metabolism
Cancer cells often reprogram lipid metabolism to support rapid proliferation, and CoA is required for fatty acid synthesis. PPAT activity contributes to CoA production, and targeting this pathway could affect cancer cell growth. However, direct evidence linking PPAT inhibition to cancer therapy is limited, and further studies are needed to evaluate PPAT as an anticancer target.
From pantetheine-phosphate adenylyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PPAT essential for bacterial growth? | CRISPR knockout or CRISPRi knockdown in Escherichia coli or Mycobacterium tuberculosis |
| What is the effect of PPAT inhibition on CoA levels? | CRISPRi knockdown plus metabolomics |
| How does PPAT mutation affect enzyme activity? | Point-mutation knock-in of active-site residues in bacterial or human cells |
| Can PPAT be used as a drug target? | CRISPRi validation combined with inhibitor treatment |
| What is the role of PPAT in human CoA homeostasis? | Knockout or overexpression of COASY in human cell lines |
| How does PPAT interact with dephospho-CoA kinase? | Tagged knock-in and co-immunoprecipitation |
How to Study the pantetheine-phosphate adenylyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | PPAT activity (formation of 3'-dephospho-CoA) | Kinetic characterization and inhibitor screening |
| X-ray crystallography | Three-dimensional structure of PPAT-ligand complexes | Structure-guided inhibitor design |
| CRISPRi | Titratable knockdown of PPAT expression | Target validation in bacteria |
| CRISPR knockout | Complete loss of PPAT function | Essentiality testing |
| Metabolomics | Levels of CoA and intermediates | Pathway flux analysis |
| Fragment-based drug discovery | Binding of small-molecule fragments to PPAT | Identification of lead inhibitors |
| Site-directed mutagenesis | Effect of active-site mutations on catalysis | Mechanistic studies |
| Co-immunoprecipitation | Protein-protein interactions (PPAT-dephospho-CoA kinase) | Bifunctional complex analysis |
Enzymatic assays for PPAT activity
PPAT activity can be measured spectrophotometrically by coupling the formation of 3'-dephospho-CoA to downstream reactions or by using radiolabeled ATP. These assays are suitable for high-throughput screening of inhibitors and for kinetic characterization of wild-type and mutant enzymes.
Structural biology
X-ray crystallography of PPAT in the ligand-unbound state and in complex with ATP and pantetheine has revealed the active-site architecture and substrate-binding residues. These structures guide the design of inhibitors and the interpretation of mutational data.
CRISPR interference and knockout
CRISPR interference (CRISPRi) allows titratable knockdown of PPAT expression in bacteria, enabling chemical validation of the enzyme as a drug target. CRISPR knockout can be used to test essentiality in organisms with efficient homologous recombination.
Metabolomics and CoA quantification
Metabolomic profiling can quantify CoA and its intermediates, such as 3'-dephospho-CoA, to assess the impact of PPAT inhibition or genetic perturbation. These methods are useful for validating target engagement and pathway flux.
How CRISPR Can Be Used to Study GO:0004595 pantetheine-phosphate adenylyltransferase activity
Knockout
CRISPR knockout of PPAT (coaD) can be used to test whether the enzyme is essential for bacterial growth. In Mycobacterium tuberculosis, CRISPR interference has been used to deplete PPAT and confirm its essentiality. Knockout models are valuable for validating PPAT as a drug target and for studying downstream metabolic effects.
Point Mutation
Point mutations in the PPAT active site can be introduced using CRISPR-based prime editing or homology-directed repair to test the role of specific residues in catalysis. Such models help dissect the catalytic mechanism and identify residues critical for substrate binding.
Knock-in
Knock-in of tagged PPAT (e.g., FLAG or GFP) allows affinity purification and localization studies. Tagged knock-in can also be used to study the bifunctional complex with dephospho-CoA kinase. These models are useful for proteomic and imaging applications.
Overexpression
Overexpression of PPAT can be achieved by CRISPR activation (CRISPRa) or by introducing a constitutive promoter. Overexpression models are useful for studying the effects of increased CoA biosynthesis on metabolism and for producing recombinant enzyme for structural studies.
How EDITGENE Supports pantetheine-phosphate adenylyltransferase activity Research
Researchers studying pantetheine-phosphate adenylyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in CoA biosynthesis, bacterial growth, or drug response. EDITGENE provides CRISPR-based cell models and screening services to interrogate PPAT function with precision.
Contact EDITGENE today to design your custom CRISPR model for pantetheine-phosphate adenylyltransferase activity research.
Frequently Asked Questions About pantetheine-phosphate adenylyltransferase activity
What is pantetheine-phosphate adenylyltransferase activity?
Pantetheine-phosphate adenylyltransferase activity (GO:0004595) is the catalysis of the reaction ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate, the penultimate step of coenzyme A biosynthesis.
What genes are involved in pantetheine-phosphate adenylyltransferase activity?
The enzyme is encoded by coaD in bacteria and by the PPAT domain of COASY in humans; it works with coaE (dephospho-CoA kinase) in the CoA pathway.
What is the function of PPAT in coenzyme A biosynthesis?
PPAT catalyzes the penultimate step of CoA biosynthesis, converting pantetheine 4'-phosphate and ATP to 3'-dephospho-CoA and diphosphate.
Why is PPAT a drug target?
PPAT is essential for CoA biosynthesis in many pathogenic bacteria, and inhibitors have shown activity against Gram-negative pathogens, making it a promising antibacterial target.
How is PPAT activity measured?
PPAT activity is measured using enzymatic assays that detect the formation of 3'-dephospho-CoA, often coupled to downstream reactions or using radiolabeled ATP.
What is the structure of PPAT?
Crystal structures of PPAT from Enterococcus faecalis and other bacteria reveal a Rossmann-like fold with a conserved active site that binds ATP and pantetheine 4'-phosphate.
Does PPAT form a complex with other enzymes?
In some bacteria, PPAT forms a bifunctional complex with dephospho-CoA kinase, enabling substrate channeling between the final two steps of CoA biosynthesis.
Can CRISPR be used to study PPAT?
Yes, CRISPR interference and knockout have been used to deplete PPAT and confirm its essentiality in Mycobacterium tuberculosis.
What diseases are associated with PPAT dysfunction?
PPAT dysfunction affects CoA homeostasis, which is linked to metabolic disorders; PPAT is also a target for antibacterial therapy.
What are the synonyms for pantetheine-phosphate adenylyltransferase activity?
Synonyms include dephospho-CoA pyrophosphorylase, 3'-dephospho-CoA pyrophosphorylase, phosphopantetheine adenylyltransferase, and PPAT activity.
Conclusion
Pantetheine-phosphate adenylyltransferase activity (GO:0004595) is a central enzymatic function in coenzyme A biosynthesis, catalyzing the penultimate step that converts pantetheine 4'-phosphate and ATP to 3'-dephospho-CoA and diphosphate. Its essential role in bacterial metabolism has made it a validated target for antibacterial drug discovery, with fragment-based inhibitors and CRISPR interference studies confirming its druggability. Structural and biochemical studies continue to refine our understanding of its catalytic mechanism and regulation. Future research using CRISPR-based models will help elucidate the role of PPAT in human metabolism and disease, and may guide the development of new therapeutics.
References
- 1. Worrall DM et al.. 1983. A bifunctional enzyme complex in coenzyme A biosynthesis: purification of pantetheine phosphate adenylyltransferase and dephospho-CoA kinase.. Biochem J 215(1):153-7 PMID: 6312972
- 2. Gupta A et al.. 2021. Phosphopantetheine Adenylyltransferase: A promising drug target to combat antibiotic resistance.. Biochim Biophys Acta Proteins Proteom 1869(2):140566 PMID: 33271445
- 3. Skepper CK et al.. 2018. Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity.. J Med Chem 61(8):3325-3349 PMID: 29551072
- 5. Martin DP et al.. 1993. Separate enzymes catalyze the final two steps of coenzyme A biosynthesis in Brevibacterium ammoniagenes: purification of pantetheine phosphate adenylyltransferase.. Biochem Biophys Res Commun 192(3):1155-61 PMID: 8389542
- 6. El Bakali J et al.. 2023. Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference.. Angew Chem Int Ed Engl 62(17):e202300221 PMID: 36757665
- 7. Yoon HJ et al.. 2011. Crystal structure of phosphopantetheine adenylyltransferase from Enterococcus faecalis in the ligand-unbound state and in complex with ATP and pantetheine.. Mol Cells 32(5):431-5 PMID: 21912874
- 8. Moreau RJ et al.. 2018. Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.. J Med Chem 61(8):3309-3324 PMID: 29498517
